PEG-conjugated triacontanol micelles as docetaxel delivery systems for enhanced anti-cancer efficacy

2019 ◽  
Vol 10 (1) ◽  
pp. 122-135 ◽  
Author(s):  
Xiaoyu Lu ◽  
Min Fang ◽  
Yue Yang ◽  
Yu Dai ◽  
Jiaqiu Xu ◽  
...  
Keyword(s):  
Delivery Systems ◽  
Anti Cancer

Cancer Treatment with Liposomes Based Drugs and Genes Co-delivery Systems

2018 ◽  
Vol 25 (28) ◽  
pp. 3319-3332 ◽  
Author(s):  
Chuanmin Zhang ◽  
Shubiao Zhang ◽  
Defu Zhi ◽  
Jingnan Cui
Keyword(s):  
Cell Cycle ◽  
Cancer Cells ◽  
Synergistic Effects ◽  
Resistance Mechanisms ◽  
Delivery Systems ◽  
Cell Cycle Checkpoints ◽  
Drug Efflux ◽  
Cancer Resistance ◽  
Cancer Models ◽  
Anti Cancer

There are several mechanisms by which cancer cells develop resistance to treatments, including increasing anti-apoptosis, increasing drug efflux, inducing angiogenesis, enhancing DNA repair and altering cell cycle checkpoints. The drugs are hard to reach curative effects due to these resistance mechanisms. It has been suggested that liposomes based co-delivery systems, which can deliver drugs and genes to the same tumor cells and exhibit synergistic anti-cancer effects, could be used to overcome the resistance of cancer cells. As the co-delivery systems could simultaneously block two or more pathways, this might promote the death of cancer cells by sensitizing cells to death stimuli. This article provides a brief review on the liposomes based co-delivery systems to overcome cancer resistance by the synergistic effects of drugs and genes. Particularly, the synergistic effects of combinatorial anticancer drugs and genes in various cancer models employing multifunctional liposomes based co-delivery systems have been discussed. This review also gives new insights into the challenges of liposomes based co-delivery systems in the field of cancer therapy, by which we hope to provide some suggestions on the development of liposomes based co-delivery systems.

Cyclodextrin polymers decorated with RGD peptide as delivery systems for targeted anti-cancer chemotherapy

2018 ◽  
Vol 37 (4) ◽  
pp. 771-778 ◽  
Author(s):  
Maurizio Viale ◽  
Rita Tosto ◽  
Valentina Giglio ◽  
Giuseppe Pappalardo ◽  
Valentina Oliveri ◽  
...  
Keyword(s):  
Cancer Chemotherapy ◽  
Delivery Systems ◽  
Rgd Peptide ◽  
Anti Cancer ◽  
Cyclodextrin Polymers

scholarly journals Polymeric Co-Delivery Systems in Cancer Treatment: An Overview on Component Drugs’ Dosage Ratio Effect

Molecules ◽  
2019 ◽  
Vol 24 (6) ◽  
pp. 1035 ◽  
Author(s):  
Jiayi Pan ◽  
Kobra Rostamizadeh ◽  
Nina Filipczak ◽  
Vladimir Torchilin
Keyword(s):  
Cancer Therapy ◽  
Cancer Treatment ◽  
Therapeutic Agent ◽  
Polymeric Nanoparticles ◽  
Therapeutic Agents ◽  
Delivery Systems ◽  
Individual Therapy ◽  
Multiple Factors ◽  
Therapeutic Outcomes ◽  
Anti Cancer

Multiple factors are involved in the development of cancers and their effects on survival rate. Many are related to chemo-resistance of tumor cells. Thus, treatment with a single therapeutic agent is often inadequate for successful cancer therapy. Ideally, combination therapy inhibits tumor growth through multiple pathways by enhancing the performance of each individual therapy, often resulting in a synergistic effect. Polymeric nanoparticles prepared from block co-polymers have been a popular platform for co-delivery of combinations of drugs associated with the multiple functional compartments within such nanoparticles. Various polymeric nanoparticles have been applied to achieve enhanced therapeutic efficacy in cancer therapy. However, reported drug ratios used in such systems often vary widely. Thus, the same combination of drugs may result in very different therapeutic outcomes. In this review, we investigated polymeric co-delivery systems used in cancer treatment and the drug combinations used in these systems for synergistic anti-cancer effect. Development of polymeric co-delivery systems for a maximized therapeutic effect requires a deeper understanding of the optimal ratio among therapeutic agents and the natural heterogenicity of tumors.

scholarly journals Albumin-based nanosystems in medicine

2018 ◽  
Vol 72 ◽  
pp. 1004-1017
Author(s):  
Bogusława Konopska ◽  
Krzysztof Gołąb ◽  
Katarzyna Juszczyńska ◽  
Jakub Gburek
Keyword(s):  
Drug Delivery ◽  
The United States ◽  
Delivery Systems ◽  
Anti Cancer ◽  
United States Food ◽  
Poorly Soluble ◽  
States Food ◽  
The Common ◽  
Low Cytotoxicity ◽  
Delivery Efficiency

Proteins are natural and safe substitutes of the synthetic polymers for the development of drug delivery systems (DDS). Few of proteins have been approved for drug delivery purposes by the United States Food and Drug Administration (FDA). Among them, albumin is the most explored carrier for synthesis of therapeutic nanoparticles. Its usefulness was determined by the common accessibility, biocompatibility and the feasibility of accumulation in tissues with increased metabolism. Albumin with its properties is particularly attractive carrier for anti-arthritis and anti-cancer drugs. It is mainly used to design delivery systems for poorly soluble substances with low permeability through biological membranes. The albumin nanoparticles are characterized by favourable pharmacokinetics, high drug delivery efficiency and low cytotoxicity. In addition, they are biodegradable, relatively easy to prepare and non-immunogenic. Interest in the exploration of clinical applications of albumin-based drug delivery carriers, especially for those at the nanoscale, has increased in recent years. A lot of research have been done to design multifunctional theranostic nanosystems that could be used for both imaging and cancer therapy. This article aims at providing an overview of already commercialized and just emerging applications of albumin-based nanosystems as drug delivery carriers.

scholarly journals Nanomedicine and Immunotherapy for Cancers

2020 ◽  
Vol 2 (5) ◽  
Author(s):  
A. A. Navas ◽  
N. Doreswamy ◽  
P. J. Joseph Francis
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Cancer Therapeutics ◽  
Delivery Systems ◽  
Metal Nanoparticle ◽  
Intranasal Route ◽  
Anti Cancer ◽  
Cancer Nanomedicine ◽  
Routes Of Drug Administration ◽  
Alternative Routes

Nanomedicine contributes to cancer therapeutics in several ways, harnessing some of the remarkable properties of nanomaterials to target tumor cells with increasing specificity. Nano-scale therapeutic strategies enable the simultaneous transport of hydrophilic and hydrophobic drugs across physical and physiological barriers like the blood-brain barrier. Alternative routes of drug administration, such as the intranasal route, have become viable, with more promising therapies for highly lethal tumors like glioblastomas. Cancer nanomedicine allows increased solubility and bioavailability of anti-cancer drugs, reducing their toxicity. Multi-drug delivery systems such as dendrimers, noble metal nanoparticle drug delivery systems, nanoparticle-based theranostics, and nano-biomarkers may well bring about a sea change in cancer therapeutics. This review presents an overview of the scope of cancer nanomedicine, including immunotherapy for cancer.

Progresses in microRNA Delivery Using Synthetic Nanovectors in Cancer Therapy

2019 ◽  
Vol 24 (31) ◽  
pp. 3678-3696 ◽  
Author(s):  
Sanaz Javanmardi ◽  
Mahmoud Reza Aghamaali ◽  
Samira Sadat Abolmaali ◽  
Ali Mohammad Tamaddon
Keyword(s):  
Gene Expression ◽  
Cancer Therapy ◽  
Pharmacological Action ◽  
Delivery Systems ◽  
Aberrant Expression ◽  
Small Noncoding Rnas ◽  
Anti Cancer ◽  
Low Cytotoxicity ◽  
Microrna Delivery ◽  
Endosomal Release

MicroRNAs are small noncoding RNAs with key roles in gene expression. It has been revealed that aberrant expression of microRNAs is related to gene expression abnormality, and they have the potential to be used as anti-cancer drugs. However, the delivery of microRNAs is limited due to barriers, such as low uptake and insufficient endosomal release, intracellular nucleases degradation, phagocytic elimination, and renal filtration. To overcome these issues, novel delivery systems are developed for improving the efficiency of microRNAs therapy ranging from viral to synthetic; some are further developed with targeted ligands for active targeting purposes. Such delivery systems provide efficient cellular uptake and endosomal release as well as low cytotoxicity and minimum unwanted host immune response. Nevertheless, more complementary studies are warranted before being applied in human studies. This review deals with recent updates on the challenges and achievements of the various nanotechnology-based gene delivery vehicles with a special emphasis on the miRNA delivery in cancer therapy. In addition, we attempted to categorize the designed delivery systems based on miRNA therapeutic molecule. The related cellular signaling pathways and pharmacological action against cancer promotion have also been highlighted.

scholarly journals A Promising Biocompatible Platform: Lipid-Based and Bio-Inspired Smart Drug Delivery Systems for Cancer Therapy

2018 ◽  
Vol 19 (12) ◽  
pp. 3859 ◽  
Author(s):  
Min Kim ◽  
Seung-Hae Kwon ◽  
Jung Choi ◽  
Aeju Lee
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Drug Delivery Systems ◽  
Controlled Drug Release ◽  
Research Area ◽  
Delivery Systems ◽  
Cancer Therapies ◽  
Smart Systems ◽  
Tumor Microenvironments ◽  
Anti Cancer

Designing new drug delivery systems (DDSs) for safer cancer therapy during pre-clinical and clinical applications still constitutes a considerable challenge, despite advances made in related fields. Lipid-based drug delivery systems (LBDDSs) have emerged as biocompatible candidates that overcome many biological obstacles. In particular, a combination of the merits of lipid carriers and functional polymers has maximized drug delivery efficiency. Functionalization of LBDDSs enables the accumulation of anti-cancer drugs at target destinations, which means they are more effective at controlled drug release in tumor microenvironments (TMEs). This review highlights the various types of ligands used to achieve tumor-specific delivery and discusses the strategies used to achieve the effective release of drugs in TMEs and not into healthy tissues. Moreover, innovative recent designs of LBDDSs are also described. These smart systems offer great potential for more advanced cancer therapies that address the challenges posed in this research area.

Sign in / Sign up

Export Citation Format

Share Document